Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.
NanoString
TIS
Vigil
gene expression profile
immune response
immunotherapy
ovarian cancer
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
12 Aug 2021
12 Aug 2021
Historique:
received:
14
06
2021
revised:
03
08
2021
accepted:
06
08
2021
entrez:
28
8
2021
pubmed:
29
8
2021
medline:
29
8
2021
Statut:
epublish
Résumé
To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil. Recurrent ovarian cancer patients ( GEP stratified by TIS Vigil demonstrates OS benefit in correlation with TIS
Identifiants
pubmed: 34452019
pii: vaccines9080894
doi: 10.3390/vaccines9080894
pmc: PMC8402348
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Vaccines (Basel). 2020 Oct 01;8(4):
pubmed: 33019493
N Engl J Med. 2016 Dec;375(22):2154-2164
pubmed: 27717299
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Cancer Lett. 2007 Aug 8;253(1):144-53
pubmed: 17353088
Gynecol Oncol. 2016 Dec;143(3):504-510
pubmed: 27678295
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
BMC Cancer. 2017 Sep 20;17(1):657
pubmed: 28931370
Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
J Immunother Cancer. 2018 Jun 22;6(1):63
pubmed: 29929551
J Cell Mol Med. 2010 Dec;14(12):2748-59
pubmed: 19780872
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
JNCI Cancer Spectr. 2020 Aug 24;4(6):pkaa077
pubmed: 33409454
F1000Res. 2018 Apr 27;7:
pubmed: 29770202
Oncology. 2010;79(3-4):187-96
pubmed: 21358206
J Clin Oncol. 2003 Jul 1;21(13):2460-5
pubmed: 12829663
Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40
pubmed: 16289860
Am J Hematol. 2019 May;94(S1):S3-S9
pubmed: 30680780
Ann Oncol. 2012 Oct;23(10):2605-2612
pubmed: 22910840
Oncology. 2019;97(2):59-74
pubmed: 31261152
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Cell Res. 2006 Feb;16(2):126-33
pubmed: 16474424
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Cell. 2004 Aug 6;118(3):277-9
pubmed: 15294153
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
JAMA Oncol. 2019 Mar 1;5(3):393-401
pubmed: 30676622
Gynecol Oncol Rep. 2020 Sep 17;34:100648
pubmed: 33364285
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
Lancet Oncol. 2020 Dec;21(12):1661-1672
pubmed: 33271095
Mol Ther. 2012 Mar;20(3):679-86
pubmed: 22186789
J Natl Cancer Inst. 2013 Aug 21;105(16):1172-87
pubmed: 23852952
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
Gynecol Oncol. 2019 Feb;152(2):243-250
pubmed: 30522700
Vaccine. 2015 Dec 16;33(51):7393-7400
pubmed: 26403368